Mullen GM, Silver MA, Malinowska K, Lawless CE, Lichtenberg RC, Barath PC, O'Keefe PJ, Robinson JA, Yeldandi V. Effective oral ganciclovir prophylaxis against cytomegalovirus disease in heart transplant recipients.
Transplant Proc 1998;
30:4110-2. [PMID:
9865316 DOI:
10.1016/s0041-1345(98)01361-x]
[Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The presented data show the combined sequential use of i.v. G for 14 days followed by PO G for 90 days is a much more effective prophylaxis for CMVD after heart transplantation than use of i.v. G for 14 days followed by PO A for 90 days. A need for hospitalization due to CMVD is significantly reduced by this new strategy. The follow-up in group II is shorter than in group I but is now at least 6 months in group II, without any new cases in the first 6 months after cardiac transplantation. Some currently unknown adverse effect of prolonged PO G, which may be present, is not identified in this analysis.
Collapse